Danaher CorporationDHREarnings & Financial Report
Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments,...
DHR Q1 FY2026 Key Financial Metrics
Revenue
$6.0B
Gross Profit
$3.6B
Operating Profit
$1.3B
Net Profit
$1.0B
Gross Margin
60.3%
Operating Margin
22.6%
Net Margin
17.3%
YoY Growth
3.7%
EPS
$1.45
Danaher Corporation Q1 FY2026 Financial Summary
Danaher Corporation reported revenue of $6.0B (up 3.7% YoY) for Q1 FY2026, with a net profit of $1.0B (up 7.9% YoY) (17.3% margin). Cost of goods sold was $2.4B, operating expenses totaled $2.2B.
Key Financial Metrics
| Total Revenue | $6.0B |
|---|---|
| Net Profit | $1.0B |
| Gross Margin | 60.3% |
| Operating Margin | 22.6% |
| Report Period | Q1 FY2026 |
Danaher Corporation Annual Revenue by Year
Danaher Corporation annual revenue history includes year-by-year totals (for example, 2025 revenue was $24.6B).
Danaher Corporation Quarterly Revenue & Net Profit History
Danaher Corporation results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $6.0B | +3.7% | $1.0B | 17.3% |
| Q4 FY2025 | $6.8B | +4.6% | $1.2B | 17.5% |
| Q3 FY2025 | $6.1B | +4.4% | $908.0M | 15.0% |
| Q2 FY2025 | $5.9B | +3.4% | $555.0M | 9.3% |
| Q1 FY2025 | $5.7B | -0.9% | $954.0M | 16.6% |
| Q4 FY2024 | $6.5B | +2.1% | $1.1B | 16.6% |
| Q3 FY2024 | $5.8B | +3.1% | $818.0M | 14.1% |
| Q2 FY2024 | $5.7B | -2.9% | $907.0M | 15.8% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.74B | $5.80B | $6.54B | $5.74B | $5.94B | $6.05B | $6.84B | $5.95B |
| YoY Growth | -2.9% | 3.1% | 2.1% | -0.9% | 3.4% | 4.4% | 4.6% | 3.7% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $78.56B | $80.61B | $77.54B | $79.12B | $81.62B | $79.90B | $83.46B | N/A |
| Liabilities | $28.66B | $29.32B | $28.00B | $28.27B | $29.29B | $28.83B | $30.93B | N/A |
| Equity | $49.90B | $51.30B | $49.54B | $50.85B | $52.33B | $51.07B | $52.53B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $1.42B | $1.51B | $2.02B | $1.30B | $1.34B | $1.66B | $2.12B | $1.32B |